Skip to Content
Learn about Adcetris a treatment of Hodgkin Lymphoma

Drug interactions between duvelisib and Mastussin DM

Results for the following 2 drugs:
duvelisib
Mastussin DM (dextromethorphan/guaifenesin)

Interactions between your drugs

Moderate

dextromethorphan duvelisib

Applies to: Mastussin DM (dextromethorphan / guaifenesin) and duvelisib

Consumer information for this interaction is not currently available.

MONITOR: Coadministration with duvelisib may increase the plasma concentrations of drugs that are primarily metabolized by the CYP450 3A4 isoenzyme. The mechanism is reduced clearance due to inhibition of CYP450 3A4 by duvelisib. The interaction may be particularly important for sensitive CYP450 3A4 substrates or those that demonstrate a narrow therapeutic index. When a single 2 mg oral dose of midazolam, a sensitive CYP450 3A4 substrate, was administered to 14 healthy adult study subjects following multiple doses of duvelisib 25 mg twice daily for 5 days, midazolam peak plasma concentration (Cmax) and systemic exposure (AUC) increased by 2.2- and 4.3-fold, respectively.

MANAGEMENT: Caution is advised if duvelisib is used in combination with sensitive CYP450 3A4 substrates or those that demonstrate a narrow therapeutic index (e.g., ergot alkaloids, colchicine, fentanyl, macrolide immunosuppressants, midazolam, triazolam, vinca alkaloids). Dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever duvelisib is added to or withdrawn from therapy.

References

  1. "Product Information. Copiktra (duvelisib)." Verastem, Inc., Needham, MA.

Drug and food interactions

No results found in our database - however, this does not necessarily mean no interactions exist. Always consult with your doctor or pharmacist.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide